United States securities and exchange commission logo June 3, 2021 N. Anthony Coles Chief Executive Officer Cerevel Therapeutics Holdings, Inc. 222 Jacobs Street, Suite 200 Cambridge, MA 02141 Re: Cerevel Therapeutics Holdings, Inc. Draft Registration Statement on Form S-1 Filed May 27, 2021 CIK No. 0001805387 Dear Dr. Coles: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Arthur R. McGivern - Goodwin Procter LLP
Together we will deliver science that takes us closer to meaningful change for people with neurological and psychiatric disorders.